ArticlePain and therapy2022

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.

John D Markman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.